CCN6 Modulates BMP Signaling via the Smad-Independent TAK1/p38 Pathway, Acting to Suppress Metastasis of Breast Cancer

Anupama Pal1,2, Wei Huang1,2, Xin Li1,2, Kathy A. Toy1,2, Zaneta Nikolovska-Coleska1,2, and Celina G. Kleer1,2

Abstract

CCN6 (WISP3) is an extracellular matrix protein that exerts tumor suppressive functions in breast cancer, where its decreased expression is a feature of advanced disease. However, neither its role nor mechanism of action in breast cancer metastasis has been established. Bone morphogenetic proteins (BMPs), which constitute ligands of the TGF-β superfamily, are multifunctional cytokines that induce epithelial–mesenchymal transition, cell invasion, and metastasis. In this study, we identify a CCN6-BMP4-TAK1 kinase signaling pathway that controls the ability of the p38 MAP kinase to regulate acinar morphogenesis and invasion of breast cells. ShRNA-mediated attenuation of CCN6 in human mammary epithelial cells led to BMP4 upregulation as a major response to exposure to the TGF-β superfamily. CCN6 attenuation also induced BMP4-mediated activation of the Smad-independent TAK1 and p38 kinases. Conversely, ectopic expression of CCN6 in breast cancer cells antagonized BMP4-mediated TAK1/p38 activation and invasive capacity, both by binding BMP4 protein as well as decreasing BMP4 protein levels. Effects on BMP4 and p38 were confirmed in vivo where they correlated with decreased metastasis. In clinical specimens, we found that CCN6 expression was inversely associated with BMP4 and phospho-p38 levels in 69% of invasive breast carcinomas examined, consistent with the functional results. Together our findings identify a novel modifier pathway through which CCN6 acts to limit breast cancer invasion and metastasis.

Introduction

The interplay between cancer cells and their microenvironment exerts a powerful influence on breast cancer behavior. The microenvironment consists of structural components of the extracellular matrix (ECM) and ECM-associated but structurally unrelated proteins, called matricellular proteins (1–3). Matricellular proteins modulate signaling pathways and facilitate epithelial-stromal cross-talk (2, 3). CCN proteins (named after Cyr61, CTGF, and NOV) are conserved ECM-associated proteins with developmental functions (3–5). Recent studies have shown that CCN proteins play important roles in tumors (6–11). Our laboratory has reported that CCN6 is expressed in normal breast epithelium but is reduced or lost in 60% of invasive breast carcinomas and in 79% of inflammatory breast cancers, the most lethal form of locally advanced breast cancer (7, 12). The high frequency of reduction or loss of CCN6 in breast cancer with high metastatic potential suggests that CCN6 may exert a role in the invasion and/or metastatic progression of human breast cancer.

Bone morphogenetic proteins (BMP), a large subgroup of ligands of the TGF-β superfamily, play crucial roles during embryonic development and tumorigenesis (13–15). BMPs activate type I and type II receptors and modulate the expression of target genes through a series of signal transduction pathways (13–15). The best characterized BMP signaling pathway is through the Smad proteins (Smad-dependent pathway), in which BMPs bind to type II receptor, thereby resulting in phosphorylation of the type I receptor. The latter then phosphorylates receptor-regulated Smads (R-Smads, Smad1, Smad5, and Smad8), which bind to the co-Smad (Smad4). R-Smad/co-Smad complexes translocate to the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Smad6 and Smad7 function as inhibitors (I-Smads) of the TGF-β/BMP pathway (13, 16). However, recent studies have confirmed that BMPs may function through a Smad-independent pathway, by which BMPs can directly activate the mitogen-activated protein kinase (MAPK)/p38 through phosphorylation of TGF-β-activated kinase 1 (TAK1; refs. 17–21). This study shows that CCN6 suppresses invasion and metastasis of breast cancer in vivo. In the absence of CCN6, there is activation of the BMP4-induced Smad-independent TAK1/p38 pathway to promote invasion. However, when present, CCN6 protein binds directly to BMP4 to antagonist BMP4-mediated...
activation of TAK1/p38 kinases and decreases the invasiveness of breast cancer cells. Taken together, this study identifies a novel CCN6/BMP4/TAK1 axis that controls p38 activity and breast cancer cell invasion.

Materials and Methods

Cell culture
HME and SUM149 cells were obtained from S. Ethier laboratory (Karmanos Cancer Institute, Detroit, MI). Cell lines were authenticated by morphology and growth characteristics and tested for mycoplasma. HME and SUM149 and their stable cell lines were selected and cultured as previously reported (7, 8). MDA-MB-231 cells were purchased from ATCC and maintained following recommended instructions.

CCN6 cloning
 CCN6 and its truncated mutants were first cloned into p3xFLAG-CMV-14 vector (Sigma) containing a Flag-tag at the C-terminus. The Flag-tagged CCN6 and its mutants were further cloned into a lentiviral pLentiLox-RSV-puro vector. The lentiviruses were packaged at the University of Michigan Vector Core. Transductions were carried out as reported (8). siRNA inhibition experiments for TAK1 are described in the Supplementary Methods.

Three-dimensional cultures and immunocytochemistry
Cells were grown on top of growth factor reduced Matrigel (Catalog # 354230; BD transduction) for 15 days following published protocols (22). Phase contrast images were taken using a Leica inverted microscope. Immunocytochemical analysis was carried out as reported (22).

For rescue experiments with recombinant human CCN6 (rhCCN6), HME-Control and CCN6 knockdown (KD) cells were grown on 3-dimensional (3D) for 4 days followed by serum starvation for 16 hours. On day 5, cells were treated with 500 ng/mL of rhCCN6 (Peprotech) in 0.1% FBS-F12 medium for 4 days with media refreshed every 2 days. On day 10, cells were put back into complete HME media and cultured for another 5 days. Phase contrast imaging, immunoblots, and immunocytochemical analyses were carried out at day 15. The percentage of single round acinar structures was calculated by counting 100 structures from 3 wells of the 8-well chamber slide.

For inhibitor studies, cells in 3D culture were treated with different inhibitors in complete medium, which was refreshed every 3 days. p38 kinase inhibitors SB203850 and SB202190, TAK1 inhibitor LLZ1640-2 or TI-2 and its inactive analog LLZ1640-4 or TI-4 were purchased from Calbiochem (EMD Chemicals). The BMP4 neutralizing antibody was evaluated using concentrations between 1 μg/mL and 7.8 mmol/mL by simultaneous fitting model. KD, k_{o}, and k_{d} were calculated by simultaneous nonlinear regression.

Invasion assay

In vitro invasion was carried out using Matrigel Invasion Chambers (BD Biosciences) according to the manufacturer's procedures, in triplicate. Invaded cells were counted under an inverted microscope after 24 hours. Details on the treatment with Bio-BMP4 and anti-BMP4 antibody are described in the Supplementary Methods.

Spontaneous metastasis assay

Firefly luciferase expressing MDA-MB-231 cells expressing Flag-Vector or CCN6-Flag were injected orthotopically into the right inguinal mammary gland (#4) of anesthetized 5-week-old athymic nude mice (Harlan Sprague-Dawley). Mice were euthanized when primary tumor volumes reached 2.0 cm3. Metastases were monitored by firefly luciferase bioluminescence imaging by BLI. Details on injection, image acquisitions, and statistical analyses can be found in Supplementary Methods.

Human breast tissue and immunohistochemistry

A high-density tissue microarray containing 71 primary invasive breast carcinomas developed and characterized by our group was employed (25). Expression of CCN6, BMP4, and phospho-p38 proteins was evaluated as either low or high based on intensity of staining and percentage of staining cells.
following published literature (7, 8, 26). Further details are provided in the Supplementary Methods.

Results

CCN6 regulates acinar-like organization and invasion in breast cells

One of the earliest morphological alterations that distinguish benign breast acini from invasive carcinoma is the loss of cellular organization and invasion (27). These histopathologic differences between benign glands and invasive carcinomas can be reproduced in 3D culture, a physiologically relevant ex vivo model (22, 28). Using this system, CCN6 KD human mammary epithelial (HME) cells are invasive compared with the polarized, self-organizing structures formed by the controls (Fig. 1A). CCN6 KD cells lack acinar polarity with loss of the basal polarity marker α6-integrin, fail to growth

![Image](https://i.imgur.com/313x431.png)

![Image](https://i.imgur.com/321x345.png)

![Image](https://i.imgur.com/321x328.png)

![Image](https://i.imgur.com/197x561.png)

![Image](https://i.imgur.com/196x543.png)

![Image](https://i.imgur.com/167x475.png)

![Image](https://i.imgur.com/216x475.png)

![Image](https://i.imgur.com/187x311.png)

![Image](https://i.imgur.com/402x310.png)

![Image](https://i.imgur.com/443x310.png)

![Image](https://i.imgur.com/443x351.png)

![Image](https://i.imgur.com/402x351.png)

![Image](https://i.imgur.com/443x392.png)

![Image](https://i.imgur.com/402x392.png)

Figure 1. CCN6 regulates acinar-like organization and invasion in HME cells. A, immunoblot and phase contrast 3D images of nontumorigenic human mammary epithelial (HME) cells with stable CCN6 knockdown (KD) and controls grown on Matrigel for 15 days. Control cells form organized acinar-like structures. In contrast, CCN6 KD induces invasion in 3D. B, representative confocal images show that CCN6 KD cells express higher phosphorylated H3 and inhibition of α6-integrin, with invasive phenotype compared with controls. Treatment with rhCCN6 (500 ng/mL) rescues the above features. C, rhCCN6 rescues the invasive phenotype of CCN6 KD HME cells and induces the formation of acinar-like structures compared with vehicle treated cells. The bar graph shows the percentage of single round acinar structures obtained by counting 100 structures. D, stable CCN6 overexpression reduced invasion in MDA-MB-231 and SUM149 breast cancer cells compared with controls. Immunoblot and representative 3D images are shown. The bar graph shows the percentage of single-round acinar-like structures calculated as in C.
arrest (positive p-Histone 3), and do not form a lumen (Fig. 1B). As observed in vivo (7), CCN6 KD HME cells show downregulation of E-cadherin expression at cell–cell borders in 3D (Supplementary Fig. S1).

The invasiveness of CCN6 KD HME cells in 3D culture was completely reversed by treatment with recombinant human CCN6 (rhCCN6) protein (Fig. 1B and C). Using a 500 ng/mL dose as previously reported (29), rhCCN6 rescued the formation of acinar-like structures with restoration of p-Histone 3; Fig. 1B and C). Similarly, stable CCN6 overexpression in SUM149 and MDA-MB-231 breast cancer cells blocked 3D invasion and induced acinar formation (Fig. 1D).

**CCN6 regulates BMP4-mediated TAK1 and p38 activation**

One of the major regulators of invasion in breast cancer is the TGF-β/BMP pathway (13–15). CCN proteins have been shown to modulate TGF-β/BMP activity (4, 30), but whether CCN6 can regulate this pathway in human cells and the underlying mechanism were unknown. The effect of CCN6 KD on the TGF-β/BMP pathway was first assessed utilizing a pathway-specific PCR array comparing CCN6 KD HME cells and scrambled controls. CCN6 KD had no significant effect on the mRNA levels of TGF-β1, TGF-β2, or on BMP1, 2, 3, 5, and 6 genes, but induced a 21-fold increase in BMP4 mRNA levels (Fig. 2A and Supplementary Table S1). Consistent with a specific role for CCN6 on BMP4 regulation, CCN6 KD led to a 6- and 25-fold increase in BAMBI and BMPER mRNA levels, 2 known extracellular regulators of BMP4 (31–33). CCN6 KD also resulted in downregulation of Inhibitor of Differentiation 1, a BMP4 target gene with functions in mammary gland development (34).

We next investigated if BMP4 signaling was activated in the invasive CCN6 KD HME cells. Western blots showed that CCN6 KD cells exhibited increased expression of BMP4 and the R-Smad, p-Smad1 (Fig. 2B and Supplementary Fig. S2A). However, no significant difference in invasion was found upon Smad1 siRNA downregulation in CCN6 KD cells compared with scrambled controls (Supplementary Fig. S2B). Moreover, CCN6 KD led to downregulation of another R-Smad, p-Smad5, and coreceptor Smad4. I-Smads, Smad6 and Smad7, function as inhibitors of TGF-β family signaling, with Smad6 preferentially blocking BMP signaling (35). We found that Smad6 was upregulated in CCN6 KD cells compared with controls (Fig. 2B). These data suggest that in the setting of CCN6 KD, the Smad-dependent pathway may not be necessary for BMP4-induced invasion.

In contrast, CCN6 KD increased p-TAK1 and its downstream molecule p-p38 MAPK, both of which are components of the BMP4 Smad-independent pathway (Fig. 2B). Further supporting the effect of CCN6 on p38 activation, rhCCN6 protein rescued the upregulation of p-p38 caused by CCN6 KD (Supplementary Fig. S3A). We also tested the effect of ectopic CCN6 on BMP4/TAK1/p38 signaling. Overexpression of CCN6 decreased BMP4 protein, p-TAK1 and p-p38 proteins in MDA-MB-231 cells compared with controls (Fig. 2B). Together, these data suggest that CCN6 regulates BMP4 signaling through the TAK1 and p38 axis.

**Activation of BMP4/TAK1/p38 signaling is required for the invasive morphology change due to CCN6 knockdown in benign breast cells**

We next determined the specific contribution of the BMP4/TAK1/p38 signaling pathway to the invasive CCN6 KD phenotype. Toward this end, individual pathway proteins were inhibited in cells growing in 3D using pharmacological inhibitors, function blocking antibodies, and siRNA-mediated knockdown. Specific inhibition of BMP4, TAK1, or p38 reduced invasion and restored acinar-like organization of CCN6 KD cells (Fig. 3A and B and Supplementary Fig. S3B). p38 inhibitors were sufficient to decrease the invasive morphology of MDA-MB-231 and SUM149 breast cancer cells (Supplementary Fig. S3C).

CCN6 KD enhanced BMP4-mediated phosphorylation of p38 (Fig. 3C). Consistent with a crucial role for BMP4 in the invasive activity of CCN6 KD, BMP4 inhibition using a function blocking
antibody was sufficient to block p38 phosphorylation in CCN6 KD cells (Fig. 3D, left). Similarly, treatment with TAK1 siRNAs or TAK1 kinase inhibitor TI-2 blunted p38 phosphorylation because of CCN6 KD (Fig. 3D, right and Fig. 3E). Together, these data show that specific activation of the BMP4/TAK1/p38 signaling cascade is required for the invasiveness triggered by CCN6 KD. Furthermore, the observed p-p38 upregulation due to CCN6 KD requires BMP4 and TAK1 kinase activation.

CCN6 overexpression decreases invasion and binds to BMP4 in breast cancer cells

Consistent with the results of 3D cultures, CCN6 overexpression decreased invasion in MDA-MB-231 cells. This effect was rescued by rhBMP4. In contrast, addition of a BMP4 blocking antibody significantly inhibited BMP4-induced invasion (Fig. 4A). CCN6 overexpression decreased BMP4, p-TAK1, and p-p38 proteins. BMP4 treatment rescued p-TAK1 and p-p38 levels, although the BMP4 antagonist had the opposite effect (Fig. 2B and 4A).

CCN6 shares the highly conserved protein motifs of the CCN family (3). It contains 4 structural modules: insulin growth factor binding protein (IGFBP), von Willebrand factor C (VWC), thrombospondin type I (TSP), and cysteine knot (CT), as well as an amino terminal signal peptide. The VWC and TSP motifs have been reported to facilitate binding of CCN proteins to BMP and TGF-β (30, 36, 37). These motifs are also present in the CCN6 protein. The VWC and TSP motifs have been reported to facilitate binding of CCN proteins to BMP and TGF-β (30, 36, 37). These motifs are also present in the CCN6 protein.
reported data together with the results shown in Fig. 4A led us to hypothesize that CCN6 may bind to BMP4 to antagonize BMP4-mediated TAK1/p38 activation leading to decreased invasion. To investigate if CCN6 and BMP4 can interact directly we used independent and complementary methods: co-immunoprecipitation and surface plasmon resonance (SPR)-based binding assay. Figure 4B shows that in vitro purified full-length rhCCN6 protein co-immunoprecipitated with purified rhBMP4 (Bio-BMP4). SPR-based binding assay confirmed the binding of immobilized rhCCN6 protein to different concentrations of Bio-BMP4 with a dissociation constant (K_d) of 200 nmol/L (Fig. 4C).
To show the interaction between CCN6 and BMP4 in breast cancer cells, and to elucidate which CCN6 motif is important for BMP4 binding, MDA-MB-231 cells were transduced with Flag-tagged full-length CCN6. Flag-tagged CCN6 truncated mutants, or the empty vector control. Immunoprecipitation was carried out with Bio-BMP4 specifically bound to streptavidin beads. Immunoblot with anti-streptavidin and anti-Flag antibodies confirmed that only ectopic full-length CCN6 and its mutant 3 (mu3) bind to Bio-BMP4 in MDA-MB-231 cells, although no binding was observed for mutants 1 and 2 (mu1 and mu2; Fig. 4D). These data show that the TSP motif of CCN6 is necessary for binding to BMP4 in MDA-MB-231 cells. The relevance of these studies to human breast cancer is further supported by simultaneous double immunostaining showing that CCN6 and BMP4 proteins colocalize in human breast cancer tissues (Supplementary Fig. S4). Next, we investigated if the ability of CCN6 to coprecipitate BMP4 is associated with inhibition of invasion. Full-length CCN6 and its mutant 3 (mu3) decreased invasion in MDA-MB-231 cells, whereas no effect was observed for mu1 and mu2, which were unable to bind to BMP4 (Fig. 4E).

CCN6 overexpression is sufficient to reduce distant metastasis

To investigate the effect of CCN6 overexpression in metastasis, we injected MDA-MB-231 expressing CCN6-Flag or Flag-Vector into the mammary fat pads of nude mice. The development of primary tumors and distant metastases was monitored by firefly luciferase bioluminescence imaging (Fig. 5A). Even though CCN6 overexpression reduced invasion of MDA-MB-231 and SUM149 cells (Fig. 1), MDA-MB-231 cells were chosen for the metastasis experiment given their ability to form spontaneous metastases compared with SUM149 cells. CCN6 overexpression decreased tumor volume compared with controls (Fig. 5B and Supplementary Fig. S5). Bioluminescence analyses revealed that all Flag-Vector mice developed metastasis (n = 14), compared with 9 of 15 (60%) of CCN6-Flag mice. The metastatic burden was significantly higher in Flag-Vector compared with CCN6-Flag mice (Fig. 5C). Kaplan–Meier survival analysis showed that CCN6-Flag mice had a median metastasis-free survival of 77 days as compared with 57 days for Flag-Vector mice (P = 0.005; Fig. 5D).

Consistent with the findings in 3D cultures, CCN6 overexpression induced in vivo phenotypic changes from mesenchymal-like to epithelial. Flag-Vector tumors contained spindled cells with low cytokeratin-18 (CK-18) and high vimentin levels. In contrast, CCN6-Flag tumors exhibited an epithelial morphology and high CK-18 expression (Fig. 5E). Providing in vivo relevance to our in vitro observations and mechanistic studies, CCN6-Flag primary tumors and lung metastasis exhibited decreased BMP4 and p-p38 staining compared with Vector-Flag tumors and metastases (Fig. 5E).

Low CCN6 protein is associated with high BMP4 and p-p38 in human invasive breast carcinomas

The significance of our novel findings to human breast cancer was validated by testing the expression of CCN6, BMP4, and p-p38 proteins in 71 primary invasive breast carcinoma tissue samples arrayed in a tissue microarray (25). Double immunostaining was carried out to detect CCN6 and p-p38 proteins. When present, CCN6 protein localized predominantly to the cytoplasm and p-p38 protein localized to the nuclei. BMP4 protein was expressed mainly in the cytoplasm, CCN6, BMP4, and p-p38 were scored as high when over 10% of the cancer cells showed moderate or strong staining, and as low when staining was present in 10% or less of the tumor cells. We found a significant association between CCN6, BMP4, and p-p38 proteins. Of the 71 tumors, 22 (31%) had low CCN6 coupled with high BMP4/p-p38 expression; and 27 (38%) had high CCN6 in association with low BMP4/p-p38 (2-tailed Fisher exact test, P < 0.0001; Fig. 6A).

Discussion

The data presented in this study reveal that CCN6 downregulation disrupts acinar morphogenesis and promotes invasion of mammary epithelial cells. In contrast, CCN6 overexpression reduces invasion and distant metastasis of breast cancer cells. Our data point to a previously unrecognized mechanism of CCN6 function by which CCN6 interacts directly with BMP4 protein in breast cancer cells to antagonize BMP4-mediated signaling through TAK1 and p38 MAPK.

A fundamental difference between normal and cancer cells is that normal breast cells are organized with the apical cytoplasm toward a central lumen, and the basal portion of the cytoplasm toward the basement membrane (27). In the breast, normal cells are organized into acini. CCN6 KD was sufficient to disrupt acinar organization and to induce a branching, disorganized, and invasive phenotype. To elaborate these conclusions, we investigated the effect of CCN6 on acinar organization utilizing 3D cultures, a system that recapitulates the normal architecture of the human breast (22, 28). Treatment with recombinant CCN6 protein completely reversed the invasiveness of CCN6 KD cells and induced the formation of well-organized acini with restoration of apical-basal cell polarity, decreased cellular proliferation, and deposition of a basement membrane.

Our group has previously reported that CCN6 loss is associated with a highly metastatic form of invasive breast carcinoma termed inflammatory breast cancer, as well as with noninflammatory invasive breast cancers with lymph node metastases (7, 12). Data presented here show for the first time that CCN6 overexpression decreases distant metastases in vivo and improves survival. We observed that CCN6 upregulation was sufficient to reprogram the phenotype of MDA-MB-231 cells from a spindle to an epithelial morphology with upregulation of cytokeratin-18. The ability of CCN6 to promote a mesenchymal-to-epithelial transition and its dependency on BMP4/TAK1/p38 signaling is a novel finding with potential therapeutic utility.

The mechanisms implicated in CCN6 tumor suppressor activity have been elusive, and CCN6 binding partners in human breast cancer were unknown. Here, we show that CCN6 binds to BMP4 in human breast cancer MDA-MB-231 cells, and this novel interaction is important for the suppressive role of CCN6.
CCN6 on invasion. We found that CCN6 and BMP4 proteins colocalize in situ, as they were detected simultaneously in both the stroma and the cancer cells of human breast cancer tissues. Further supporting our results, the CCN6 zebrafish ortholog (zwisp3) was found to immunoprecipitate with BMP4, and CCN6 overexpression antagonized BMP and Wnt signaling in developing zebrafish (37). Another CCN family member, CTGF (also called CCN2), has been shown to physically interact with BMP4 in vitro, antagonizing BMP4 activity by preventing its binding to BMP receptors (30). However, the consequences of these interactions on downstream signal transduction pathways as related to cancer progression have not been investigated. Similarly, the possibility that CCN proteins would directly control BMP4-mediated TAK1 and p38 signaling had not been considered previously.

BMP4, an extracellular signaling protein that belongs to the TGF-β superfamily, is essential for development because Bmp4 null mice are embryonic lethal (38). In addition, BMP4 upregulation is a common event in the pathogenesis of human carcinomas, including breast cancer (39–41). The best studied mechanism of BMP4 action is by activating Smad-dependent signaling pathways through Smad1/5/8 (13, 16). In recent years, BMP4 has been shown to activate Smad-independent pathways, including p38 MAPK through activation of TAK1, a MAPKKK family member (17–20); but the responsible mechanisms are still ill defined. Through a combination of knockdown

Figure 5. CCN6 overexpression in MDA-MB-231 cells is sufficient to decrease distant metastasis. A, MDA-MB-231-CCN6-Flag-Luc and Flag-Vector-Luc were injected in the mammary fat pads of nude mice, n = 15 mice/group. Representative pictures of luciferase imaging showing primary tumors (P) and metastasis (M). B, CCN6-Flag cells formed significantly smaller primary tumors compared with controls (mean tumor volume ± SD). C, CCN6 overexpression significantly decreased the metastatic burden. The median survival was 57 days versus 77 days for Flag-Vector and CCN6-Flag mice, respectively (Kaplan–Meier log rank P = 0.005). E, photomicrographs of xenografts and lung metastasis of CCN6-Flag and Flag-Vector mice. CCN6 overexpression changed the tumor morphology from mesenchymal-like to epithelial, with upregulation of the epithelial marker cytokeratin-18 (CK-18). CCN6-Flag primary tumors and lung metastasis exhibit decreased BMP4 and p-p38 proteins. Black arrows show metastases in the lung of CCN6-Flag and Flag-Vector mouse (200× magnification).
and rescue strategies, we have attempted to dissect the key signaling components linking CCN6 to BMP4 signaling pathways. The results reported here indicate that CCN6 binds to BMP4 in human breast cancer cells and that the TSP motif of CCN6 is required for this interaction. Our data show that the principal consequence of the interaction between CCN6 and BMP4 proteins in breast cancer is the inhibition of the BMP4/TAK1/p38 axis leading to reduced invasion. Conversely, in the absence of CCN6, BMP4 is upregulated, resulting in increased activity of the BMP4/TAK1/p38 axis to promote invasion.

The in vivo relevance of the mechanistic link between CCN6, BMP4, and p-p38 proteins was determined by testing their expression in xenografts and human tissue samples. CCN6 overexpression decreased the levels of BMP4 and p-p38 proteins in primary and metastatic tumors. In human breast cancer, 22 of 29 (76%) invasive carcinomas expressing low CCN6 were positive for BMP4 and p-p38; although 27 of 42 (64%) tumors with high CCN6 were negative for BMP4 and p-p38 proteins. From a clinical perspective, the role of CCN6 as a regulator of the BMP4/TAK1/p38 cascade is of particular interest because autocrine or paracrine activation of this pathway could be detectable and targetable in tumors. For example, a recent study in colon cancer showed that TAK1 inhibition using a synthetic TAK1 inhibitor decreased tumor progression in preclinical models of TAK1-dependent cancers (42, 43). Based on our data, CCN6 emerges as a logical target to inhibit BMP4-mediated activation of TAK1 and p38 in CCN6 deficient tumors with increased activity of this pathway.

In conclusion, our results show a previously undescribed mechanism of CCN6 tumor suppression in breast cancer. These data show that CCN6 protein has metastasis suppressor functions and uncover an underlying molecular mechanism by which CCN6 influences the BMP4/TAK1/p38 axis to regulate
invasion. Our data provide evidence that CCN6 may be a rational therapeutic target for development of treatments to halt breast cancer metastasis and improve clinical outcome.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A. Pal, W. Huang, C.G. Kleer
Development of methodology: A. Pal, W. Huang, C.G. Kleer
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Pal, W. Huang, X. Li, K. A. Toy, C.G. Kleer
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Pal, W. Huang, C.G. Kleer
Writing, review, and/or revision of the manuscript: A. Pal, W. Huang, C.G. Kleer
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Pal, W. Huang, K.A. Toy, C.G. Kleer

Carried out and analyzed results from the binding affinity: A. Pal, Z. Nikolovska-Coleska
Study supervision: C.G. Kleer

Acknowledgments
We thank Maria E. Gonzalez and Heather M. Moore, members of the Kleer lab, for helpful suggestions and critical reading of the manuscript. We thank Robin Kunkel for artwork in Figure 6B.

Grant Support
This work was supported by NIH grants R01 CA107469, R01 CA125577, and U01CA154224 (C.G. Kleer), the University of Michigan’s Cancer Center Support Grant (5 P30 CA46590).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 19, 2012; revised July 11, 2012; accepted July 12, 2012; published OnlineFirst July 17, 2012.

References

www.aacajournals.org Cancer Res; 72(18) September 15, 2012 4827

Downloaded from cancerres.aacajournals.org on April 4, 2017. © 2012 American Association for Cancer Research.


CCN6 Modulates BMP Signaling via the Smad-Independent TAK1/p38 Pathway, Acting to Suppress Metastasis of Breast Cancer

Anupama Pal, Wei Huang, Xin Li, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-0154

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/07/18/0008-5472.CAN-12-0154.DC1

**Cited articles**
This article cites 41 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/18/4818.full.html#ref-list-1

**Citing articles**
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/72/18/4818.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.